Skip to main content

Table 1 Sociodemographic and clinical characteristics of patients by status at end of treatment by univariate Cox proportional-hazards regression (n = 565).

From: Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis

Characteristics Death during treatment
N (%)
Alive throughout treatment
N (%)
p value
N 37 528  
Mean age at diagnosis ± SD 45.0 ± 16.2 40.7 ± 13.5 0.03
   Median (Min-Max) 41 (22-88) 38 (18-94)  
Male Gender 29 (78.4) 423 (80.1) 0.95
Race American Indian 0 9 (1.7) 0.99
  African American/Black 13 (35.1) 187 (35.4) 0.97
  Asian/Pacific Islander 1 (2.7) 10 (1.9) 0.73
  White 23 (62.2) 322 (61.0) Ref
Hispanic ethnicity 7 (18.9) 159 (30.1) 0.16
US born 31 (83.8) 364 (68.9) 0.03
HIV positive 24 (64.9) 180 (34.1) 0.02
   HAART during tuberculosis therapy 1/24 (4.2) 27/180 (15.0) 0.10
   History of opportunistic infection 21/24 (87.5) 101/180 (56.1) 0.01
   CD4 count    
≤ 200 cells/μL1 17/19 (89.5) 108/156 (69.2) 0.14
Median CD4 count at diagnosis (IQR)1 68 (34-104) 105 (47-269) 0.06
Received directly observed therapy2 Yes 28 (75.7) 251 (47.7) 0.02
  Partial* 4 (10.8) 90 (17.1) 0.67
  No 5 (13.5) 185 (35.2) Ref
Episode of inadequate therapeutic regimen 25 (67.6) 161 (30.5) 0.01
During intensive phase3 24 (64.9) 129/525 (24.6) 0.001
Median duration of inadequate treatment (days) (IQR) (n = 153) 23 (6-35) 18 (9-34) 0.18
During continuation phase4 10/33 (30.3) 116/523 (22.2) 0.44
Median duration of inadequate treatment (days) (IQR) (n = 126) 37 (24-50) 29 (13-50) 0.24
   Due to non-adherence 22 (59.5) 142 (26.9) 0.01
During intensive phase3 21 (56.8) 109/525 (20.8) 0.001
Median duration of inadequate treatment (days) (IQR) (n = 130) 8 (5-28) 15 (7-24) 0.13
During continuation phase4 10/33 (30.3) 108/523 (20.7) 0.64
Median duration of inadequate treatment (days) (IQR) (n = 118) 30 (16-50) 29 (14-53) 0.11
   Due to adverse reaction5 10 (27.0) 49/527 (9.3) 0.10
During intensive phase5 7 (18.9) 39/527 (7.4) 0.21
Median duration of inadequate treatment (days) (IQR) (n = 46) 29 (8-39) 14 (6-38) 0.75
During continuation phase5 3 (8.1) 18/527 (3.4) 0.98
Median duration of inadequate treatment (days) (IQR) (n = 21) 25 (1-31) 14 (7-20) 0.40
Hospitalized for tuberculosis6 29 (78.4) 253/526 (48.1) 0.003
Homeless within 1 year of diagnosis7 16/27 (59.3) 138/356 (38.8) 0.04
Substance abuse at diagnosis 23 (62.2) 228 (43.2) 0.13
Sputum smear positive 27 (73.0) 233 (44.1) 0.004
Sputum culture positive 34 (91.9) 471 (89.2) 0.62
Extrapulmonary disease in addition to pulmonary disease 18 (48.7) 143 (27.1) 0.13
Cavitary disease 4 (10.8) 129 (24.4) 0.12
Any prior medical condition 25 (67.6) 288 (54.6) 0.13
  1. 1) Excluding 29 with missing data for CD4 cell count. 2) Excluding 2 with missing data for directly observed therapy. * Partial DOT = DOT used for less than the full duration of treatment (clinicians opted to transition select patients to self-administered therapy (SAT) at the end of the intensive phase of treatment, or initiated DOT in patients previously treated by SAT in whom clinical, radiographic or microbiologic response to treatment was delayed). 3) Excluding 3 with missing data for intensive phase. 4) Excluding 9 with missing data for continuation phase. 5) Excluding 1 with missing data for adverse reaction. 6) Excluding 2 with missing data for hospitalization. 7) Excluding 182 with missing data for housing status.